SCHEMBL24917570

SCHEMBL24917570

CC(=O)O[C@H]1[C@@H](O)[C@](C)(c2ccc3c(NC(=O)c4ccccc4)ncnn23)O[C@@H]1CO

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TMPRSS2 O15393 1/20 0.48
▸ PRMT6 Q96LA8 1/20 0.35
▸ POLB P06746 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.32
▸ ADORA3 P0DMS8 1/20 0.32
▸ NPC1 O15118 2/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ ATM Q13315 1/20 0.32
▸ RAB9A P51151 1/20 0.31
▸ XDH P47989 1/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ NTRK1 P04629 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25912595 0.91 TMPRSS2 (0.47) TMPRSS2POLBTDP1ADORA3NPC1
SCHEMBL25912620 0.90 TMPRSS2 (0.46) TMPRSS2POLBTDP1ADORA3ALDH1A1
SCHEMBL24917263 0.88 TMPRSS2 (0.46) TMPRSS2PRMT6POLB
SCHEMBL24789767 0.88 TMPRSS2 (0.58) TMPRSS2TDP1ADORA3NPC1ALDH1A1
SCHEMBL24917569 0.87 TMPRSS2 (0.63) TMPRSS2PRMT6POLBTDP1ADORA3
SCHEMBL26136380 0.87 TMPRSS2 (0.63) TMPRSS2PRMT6POLBTDP1ADORA3
SCHEMBL24791255 0.87 TMPRSS2 (0.43) TMPRSS2POLB
SCHEMBL24916813 0.86 TMPRSS2 (0.45) TMPRSS2TDP1ADORA3HTT
SCHEMBL24791234 0.86 TMPRSS2 (0.47) TMPRSS2PRMT6POLBTDP1ADORA3
SCHEMBL25912420 0.86 TMPRSS2 (0.40) TMPRSS2XDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230233593-A1 ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS VenatoRx Pharmaceuticals, Inc. 2023-07-27 — — US disclosed
US-11638715-B2 Orally-bioavailable nucleoside analogs VenatoRx Pharmaceuticals, Inc. (US) 2023-05-02 — — US disclosed
US-20230024722-A1 ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS VenatoRx Pharmaceuticals, Inc. 2023-01-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230024722-A1 ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS SLC29A2, SLC29A1, PNP TMPRSS2 100/4885PRMT6 906/4885POLB 95/4885
US-11638715-B2 Orally-bioavailable nucleoside analogs SLC29A2, SLC29A1, PNP TMPRSS2 100/4885PRMT6 906/4885POLB 95/4885
US-20230233593-A1 ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS SLC29A2, SLC29A1, PNP TMPRSS2 100/4885PRMT6 906/4885POLB 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback